Form 4 Healthequity Inc: Sunil Rajasekar (EVP Chief Prod & Strat Officer) For: 22 April
This article reports a Form 4 filing for Healthequity Inc., detailing an insider transaction by Sunil Rajasekar, Executive Vice President, Chief Product & Strategy Officer. The filing pertains to activity on April 22. The article provides the title of the filing and identifies the insider involved.
Barclays lifts target for HealthEquity stock to USD 115.00
Barclays has raised its price target for HealthEquity (HQY) stock to USD 115.00 from USD 110.00, maintaining an "Overweight" rating. This adjustment follows HealthEquity's report of USD 350.73 million in revenue for its second quarter, an increase of 7.63% year-over-year. The company's stock was trading at EUR 84.75 at Lang & Schwarz and USD 95.28 on Nasdaq, with an average analyst target of USD 112.20.
HealthEquity (NASDAQ:HQY) EVP Sunil Rajasekar Sells 108 Shares of Stock
HealthEquity EVP Sunil Rajasekar sold 108 shares of the company's stock for $11,404.80 on August 24th, reducing his total holdings by 0.20%. This transaction follows a recent purchase of 108 shares on October 15th for $9,755.64. The company reported strong quarterly earnings, beating analyst estimates with EPS of $1.24 and revenue up 95.5% year-over-year, while analysts maintain a "Moderate Buy" rating for HQY.
HealthEquity EVP Sunil Rajasekar Reports Delayed Disclosure of Short Sales and Covering Trades
HealthEquity EVP Sunil Rajasekar filed a delayed Form 4 revealing four transactions involving short sales and covering purchases of company stock between April and October 2026. These trades, executed in broker-managed discretionary accounts, were reported late as Rajasekar was unaware of them at the time. He voluntarily repaid approximately $1,650 to HealthEquity, representing all profits subject to Section 16(b) of the Securities Exchange Act.
HealthEquity EVP Sunil Rajasekar sells $13,309 in stock
HealthEquity EVP Sunil Rajasekar reported sales and purchases of company common stock. The transactions involved sales totaling $13,309 and purchases totaling $11,942, with Rajasekar voluntarily paying $1,650 to HealthEquity for profits under Section 16(b). Following these transactions, Rajasekar beneficially owns 53,405 shares, and the stock is considered undervalued by InvestingPro.
Form 4 Healthequity Inc: Sunil Rajasekar (EVP Chief Prod & Strat Officer) For: 22 April
This article reports a Form 4 filing for Healthequity Inc, detailing transactions by Sunil Rajasekar, the EVP Chief Product & Strategy Officer, for April 22. The filing indicates insider activity at Healthequity, a common occurrence that investors monitor for insights into a company's financial health and management's confidence.
Lobbying Update: $400,000 of HEALTHEQUITY INC. lobbying was just disclosed
HEALTHEQUITY INC. (HQY) disclosed $400,000 in lobbying expenditures for Q3 2026, focusing on tax-advantaged health savings vehicles and various healthcare acts. The article also details recent congressional stock trades, insider trading activities, hedge fund movements, and analyst ratings for HQY.
An executive sold short and bought HealthEquity (HQY) shares, voluntarily paying it about $1,650.
Sunil Rajasekar, EVP Chief Prod & Strat Officer at HealthEquity, reported short sales and subsequent purchases of HQY shares that were executed in broker-managed discretionary accounts without his knowledge. He voluntarily paid approximately $1,650 to HealthEquity, representing all "profits" under Section 16(b) of the Securities Exchange Act. The transactions involved short sales on April 22, 2026, and August 24, 2026, and covering purchases on July 8, 2026, and October 15, 2026.
Curated Wealth Partners LLC Sells 316,167 Shares of HealthEquity, Inc. $HQY
Curated Wealth Partners LLC significantly reduced its stake in HealthEquity, Inc. by selling 316,167 shares, retaining only 2,908 shares valued at $257,000. Despite this sell-off, analyst sentiment for HQY remains positive with a "Moderate Buy" rating and an average price target of $112.20. HealthEquity also reported strong quarterly earnings, exceeding estimates with $1.24 EPS and a 95.5% year-over-year revenue increase.
HealthEquity, Inc. (NASDAQ:HQY) Stock Rated "Moderate Buy" by Wall Street Analysts
HealthEquity, Inc. (NASDAQ:HQY) has received a "Moderate Buy" consensus rating from Wall Street analysts, with an average 12-month price target of $112.20. The company recently reported strong quarterly earnings, beating estimates with an EPS of $1.24 and revenue growth of 95.5% year over year. Institutional investors hold a significant stake in HQY, and the company has seen recent institutional buying activity.
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Healthequity (HQY)
Two healthcare companies, Humacyte (HUMA) and Healthequity (HQY), have received optimistic evaluations from analysts. H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating for Humacyte with a $4.00 price target, while Bank of America Securities analyst Allen Lutz maintained a Buy rating for Healthequity with a $125.00 price target. Both analysts are highly rated and specialize in the Healthcare sector.
HealthEquity, Inc. (HQY) Stock Forecasts
Argus has lowered its target price for HealthEquity, Inc. (HQY) to $99.00, while the current price is $92.03. The company, which provides solutions for healthcare saving and spending decisions, operates in the healthcare sector. Investors can access a full report for more detailed analysis.
HealthEquity stock trades at a 33.29 earnings multiple
HealthEquity stock is trading at an earnings multiple of 33.29, with a market capitalization of $7.6 billion as of October 15, 2026. The company's 52-week stock price ranged from $72.76 to $107.62. HealthEquity, listed on Nasdaq under HQY, provides technology-enabled services for health savings accounts.
Jefferies examines HealthEquity stock short interest rise By Investing.com
Jefferies reported that short interest in HealthEquity (NASDAQ:HQY) shares increased to 7.2% of diluted shares outstanding by September 30, driven by investor concerns. Key factors include the company's limited exposure to near-term treasury rate upside, uncertainties in marketplace adoption and terminal value, and declining cash balances per Health Savings Account (HSA). Despite declining HSA cash balances, Jefferies noted increased member engagement and a significant rise in investment-linked HSAs.
How Healthequity Inc. (HQY) Affects Rotational Strategy Timing
Healthequity Inc. (HQY) shows strong near-term sentiment but a neutral mid- to long-term outlook, with support currently being tested. AI-generated strategies include a long position trading strategy targeting a 12.5% gain, a momentum breakout strategy, and a risk-hedging short strategy. The analysis highlights key support and resistance levels across different time horizons.
The commercial chief was terminated without cause at HealthEquity (HQY); management will split his duties.
HealthEquity, Inc. (HQY) announced the termination of its Chief Commercial Officer, Michael Fiore, without cause, effective October 5, 2026. His responsibilities will be distributed among other management members. Fiore is set to receive negotiated severance payments and benefits, contingent on him signing a release of claims and adhering to restrictive covenants, as detailed in the company's May 13, 2026 proxy statement.
HealthEquity, Inc. (HQY) Stock Forecasts
Argus has raised its target price for HealthEquity, Inc. (HQY) to $100.00, according to a report published on October 07, 2026. HealthEquity Inc. provides solutions for consumers to manage healthcare savings and spending. The current price of HQY stock is $92.61.
HealthEquity (NASDAQ:HQY) Upgraded at Wall Street Zen
HealthEquity (NASDAQ:HQY) has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, contributing to a "Moderate Buy" consensus among analysts with an average price target of $112.20. The company recently surpassed quarterly earnings expectations, reporting $1.24 EPS against a $1.19 consensus and significantly increased revenue by 95.5% year-over-year to $350.73 million. Institutional ownership is high at 99.55%, with major new positions like BlackRock's $1.02 billion investment, though a company director sold shares worth $798,000.
Tax withholding requires Delano Ladd’s planned $98.4K share sale at HealthEquity (HQY).
HealthEquity officer Delano Ladd is planning to sell 1,080 common shares valued at approximately $98,447.74 around October 6, 2026. This sale is a "sell-to-cover" transaction to meet tax withholding obligations from restricted-stock vesting, not a discretionary trade. Ladd previously sold 1,087 shares on July 8, 2026, for $103,355.31.
One investment adviser reports a passive stake of 7.01 million shares in HealthEquity (HQY).
Wasatch Advisors has filed an amended ownership report for HealthEquity, Inc. (HQY), disclosing a beneficial ownership of 7,011,469 shares, which represents 8.5% of the class, as of September 30, 2026. The investment adviser holds sole voting power over 4,677,076 shares and sole dispositive power over all 7,011,469 shares. This filing is classified as a SCHEDULE 13G/A, indicating a passive investment.
Form 4 Healthequity Inc For: 8 October By Investing.com
This article reports on a Form 4 filing for Healthequity Inc. on October 8, 2026. The brief announcement provides the company's stock symbol (HQY) and its current performance on that date, noting a slight decrease. It primarily serves as a notice of the filing rather than an in-depth analysis.
Form 4 Healthequity Inc For: 8 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Healthequity Inc. for October 8th. The content is brief and primarily serves as a notification of the filing, without providing additional details or analysis of the filing itself. The article also includes various market data, trending stocks, and related news headlines.
1,230 shares were delivered or withheld for HealthEquity (HQY) CEO Scott Cutler.
HealthEquity, Inc. (HQY) President and CEO Scott Cutler had 1,230 common shares delivered or withheld on October 6, 2026, for payment of exercise price or tax liability at $91.1553 per share. Following this transaction, his direct common stock position in the company stands at 175,175 shares. This information was detailed in a Form 4 SEC filing.
Form 4 Healthequity Inc For: 8 October By Investing.com
The article reports on a Form 4 filing for Healthequity Inc (HQY) on October 8th, indicating insider trading activity. It provides no further details on the specific transactions or their implications, focusing solely on the announcement of the filing. The article is brief and primarily serves as a notification of the regulatory document.
To cover taxes, HealthEquity (HQY) officer Stephen Neeleman proposes selling 1,095 shares.
HealthEquity, Inc. (HQY) officer and director Stephen Neeleman has proposed selling 1,095 common shares, valued at $99,815.07, around October 6, 2026. This sale is mandated by the issuer to fund tax withholding obligations through a "sell-to-cover" transaction, not as a discretionary trade. Neeleman also sold 1,103 shares for $104,876.64 on July 8, 2026.
Tax withholding requires a proposed 2,032-share sale at HealthEquity (HQY).
HealthEquity's former EVP, CCO, Michael Henry Fiore, plans to sell 2,032 common shares on October 6, 2026, valued at $185,227.59. This sale is not a discretionary trade but is mandated by HealthEquity's equity incentive plan to cover a tax withholding obligation through a "sell to cover" transaction. The filing also notes previous sales by Fiore in July 2026.
Former executive Fiore holds 50,212 direct shares in HealthEquity (HQY) after disposing of 2,032 shares.
Former HealthEquity EVP, CCO Michael Henry Fiore disposed of 2,032 shares of common stock on October 6, 2026, at $91.1553 per share, primarily for tax liability or exercise price payment. Following this transaction, Fiore directly holds 50,212 shares of HealthEquity (HQY). This insider trading activity was reported in a Form 4 filing with the SEC.
Form 144 HEALTHEQUITY For: 8 October By Investing.com
This article announces the filing of Form 144 for HEALTHEQUITY (HQY) on October 8th, as reported by Investing.com. It is a brief, factual update indicating a financial disclosure for the company.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HealthEquity (HQY) stock is recommended for holding due to its strong fiscal second-quarter 2027 performance and significant growth in Health Savings Accounts (HSAs). The company has benefited from AI and digital innovation, leading to scalable efficiency and improved margins. However, potential data security threats and related lawsuits pose a risk to its long-term growth and margin profile.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HealthEquity (HQY) stock has gained from its business model and strategy, with a solid second-quarter fiscal 2027 performance and strength in Health Savings Accounts (HSAs) expected to drive further growth. AI and digital innovations have also contributed to scalable efficiency and lower service costs. However, data security threats and a related class action lawsuit remain significant concerns that could impact the company's long-term margin and growth profile.
HealthEquity stock adds a director after Q2 revenue reaches USD 350.73 million
HealthEquity (HQY) reported Q2 fiscal 2027 revenue of USD 350.73 million, a 7.6 percent increase year-over-year, and appointed Moody's CFO Noémie Heuland to its board, effective September 24, 2026, to enhance finance and technology expertise. The company's stock was trading at USD 90.04 on October 2, 2026, and analysts maintain a Moderate Buy rating with an average target of USD 112.20. Despite a 16.34 percent drop from its 52-week high, HealthEquity raised its fiscal 2027 revenue guidance.
HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors
HealthEquity, Inc. (NASDAQ: HQY) has announced the appointment of Noémie Heuland, Chief Financial Officer of Moody’s Corporation (NYSE: MCO), to its board of directors, effective September 24, 2026. Heuland will also serve on the Audit and Risk Committee and Cybersecurity and Technology Committee. This appointment expands the Board to 11 directors and is expected to bring valuable financial and strategic perspective to HealthEquity's continued growth.
A director reports 2,033 shares at HealthEquity (HQY), with delivery upon June 2027 vesting.
HealthEquity director Noemie Clemence Heuland has reported an initial direct common-stock position of 2,033 shares. These shares are part of restricted stock units which will vest in full on the date of the company's annual stockholder meeting in June 2027, with delivery upon vesting. This filing indicates a moderate impact with neutral sentiment, according to Rhea-AI.
HealthEquity Appoints Moody’s CFO Noémie Heul
The article announces that HealthEquity has appointed Noémie Heuland, formerly the Chief Financial Officer of Moody's Corporation, as its new Chief Financial Officer. She will also serve as Executive Vice President and Treasurer, reporting directly to HealthEquity's President and CEO, Jon Kessler. Heuland brings extensive financial leadership experience from her previous role at Moody's and will be instrumental in guiding HealthEquity's financial strategy.
HealthEquity adds Moody’s CFO to board of directors
HealthEquity, Inc. announced the election of Noémie Heuland, CFO of Moody's Corporation, to its board of directors, effective September 24. She will serve on the Audit and Risk Committee and the Cybersecurity and Technology Committee, expanding the board to 11 directors. Heuland brings extensive financial leadership experience from Moody's, Dayforce, Inc., and SAP.
HealthEquity adds Moody’s CFO to board of directors By Investing.com
HealthEquity, Inc. (NASDAQ:HQY) has appointed Noémie Heuland, the current Chief Financial Officer of Moody's Corporation (NYSE:MCO), to its board of directors. Her appointment expands the board to 11 members, with nine being independent. Heuland will serve on the Audit and Risk Committee and Cybersecurity and Technology Committee.
Noémie Heuland joins HealthEquity board as CFO of Moody’s, to serve on Audit & Cybersecurity committees
HealthEquity (HQY) has appointed Noémie Heuland, the Chief Financial Officer of Moody's Corporation, to its Board of Directors, expanding the board to eleven members. Effective September 24, 2026, Heuland will serve on the Audit and Risk Committee and the Cybersecurity and Technology Committee. This appointment follows previous financial dealings between HealthEquity and Moody's controlled subsidiaries.
HealthEquity adds Moody’s CFO to board of directors By Investing.com
HealthEquity, Inc. (NASDAQ:HQY) has announced the election of Noémie Heuland, CFO of Moody’s Corporation (NYSE:MCO), to its board of directors, effective September 24. She will serve on the Audit and Risk Committee and the Cybersecurity and Technology Committee, expanding the board to 11 directors. Heuland brings extensive financial leadership experience from her roles at Moody's, Dayforce, and SAP.
HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors
HealthEquity, Inc. announced the appointment of Noémie Heuland, CFO of Moody's Corporation, to its board of directors, effective September 24, 2026. Heuland will also serve on the Audit and Risk Committee and Cybersecurity and Technology Committee. Her extensive experience in finance and technology is expected to be valuable as HealthEquity continues its growth and innovation.
HQY5271388 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the HealthEquity, Inc. 4.5% 01-OCT-2029 bond (HQY5271388 FINRA), covering key facts such as issuer details, issue and maturity dates, and face value. It outlines the bond's semi-annual fixed-rate coupon payments and includes a schedule of upcoming payouts. The profile also touches upon redemption information and encourages users to sign up for full access to credit risk assessments and historical data.
HealthEquity stock holds near USD 94.52 as earnings beat estimates
HealthEquity, Inc. (HQY) opened at USD 94.52 on Nasdaq, with its latest quarterly earnings exceeding analyst estimates. The company reported EPS of USD 1.24, beating consensus by USD 0.05, and revenue of USD 350.73 million, surpassing expectations. Analysts maintain a "Moderate Buy" consensus with an average 12-month price target of USD 112.20, suggesting an 18.7 percent upside.
HealthEquity, Inc. (HQY) Stock Analysis: Unpacking a 25% Upside Potential in the Healthcare Sector
HealthEquity, Inc. (HQY) demonstrates a strong position in the healthcare technology sector with a $7.87 billion market capitalization and robust offerings like HSAs and FSAs. Analysts overwhelmingly rate HQY as a 'Buy,' predicting a potential upside of approximately 25.43% with an average target price of $119.33. The company's focus on technology-enabled services and positive growth indicators make it an intriguing opportunity for investors in the burgeoning healthcare technology sector.
After gifting 1,500 shares, HealthEquity (HQY) founder still holds 137,565
HealthEquity (HQY) founder Stephen Neeleman gifted 1,500 indirectly held shares on September 17, 2026, from a trust. Despite this bona fide gift, he retains a substantial direct holding of 137,565 common shares and several tranches of stock options. The transaction was not part of a Rule 10b5-1 trading plan.
Bank of America Corp DE Invests $103.57 Million in HealthEquity, Inc. $HQY
Bank of America Corp DE has acquired a significant stake in HealthEquity, Inc., purchasing 1.15 million shares valued at approximately $103.6 million, making it a 1.37% owner of the company. This investment comes as HealthEquity reported strong quarterly results, exceeding expectations with $1.24 EPS and a 95.5% year-over-year revenue increase. Despite positive analyst sentiment and a "Moderate Buy" consensus rating, there has been insider selling of 12,456 shares totaling about $1.26 million in the past three months.
HealthEquity Founder Stephen Neeleman Reports Gift of 1,500 Shares in Form 4 Filing
Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc. (NASDAQ: HQY), submitted a Form 4 detailing a gift of 1,500 shares of common stock on September 17, 2026. Following this transaction, Neeleman directly holds 137,565 shares and has significant indirect holdings through trusts, family entities, and stock options. The filing provides a comprehensive overview of his beneficial ownership in the company.
Barclays Maintains HealthEquity(HQY.US) With Buy Rating, Raises Target Price to $115
Barclays has reiterated its Buy rating on HealthEquity (HQY.US) and increased its target price from $105 to $115. This update reflects the firm's continued confidence in HealthEquity's financial prospects and market position. The new target price suggests an anticipated upside for the stock.
California State Teachers Retirement System Purchases 8,732,150 Shares of HealthEquity, Inc. $HQY
The California State Teachers Retirement System significantly increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 8,679.7%, purchasing an additional 8.73 million shares. This brings their total holdings to 8.83 million shares, valued at approximately $797.8 million. HealthEquity has also reported strong financial performance, exceeding quarterly earnings and revenue expectations, and institutional investors now collectively own 99.55% of the company's stock.
Amundi Increases Stake in HealthEquity, Inc. $HQY
Amundi increased its stake in HealthEquity (NASDAQ:HQY) by 33.6% in the second quarter of 2026, bringing its total holdings to 90,327 shares valued at $8.16 million. HealthEquity exceeded Q2 earnings estimates with $1.24 EPS and saw a 95.5% year-over-year revenue increase. Analysts maintain a "Moderate Buy" rating with an average price target of $111.87, despite recent insider share sales totaling $1.26 million.
Understanding Momentum Shifts in (HQY)
This article analyzes Healthequity Inc. (NYSE: HQY), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 44.5:1 risk-reward setup targeting a 12.8% gain against a 0.3% risk. The article provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
29,000 Shares in HealthEquity, Inc. $HQY Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al
VIRGINIA RETIREMENT SYSTEMS ET Al acquired 29,000 shares of HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, valued at approximately $2.62 million. Institutional investors now own 99.55% of HQY's outstanding shares, while company insiders sold 12,456 shares worth about $1.26 million. HealthEquity reported strong quarterly earnings, exceeding expectations with $1.24 EPS and $350.73 million in revenue, a 95.5% year-over-year increase.
